Exome Asset Management’s Wave Life Sciences WVE Stock Holding History

Exome Asset Management’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$218K	Buy	+30,000	New	+$391K	0.11%	55

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GSK plc London $599M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Exome Asset Management's WVE Position: Q1 2026 in Review

Exome Asset Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 421,488 shares — an estimated $5.49M sold.

Exome Asset Management first reported a position in WVE in Q2 2024 and held it in 2 quarters. The position peaked at $7.17M in Q4 2025. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

Exome Asset Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
Exome Asset Management sold 421,488 Wave Life Sciences shares in Q1 2026, an estimated $5.49M.
Exome Asset Management first reported a position in Wave Life Sciences in Q2 2024 and held it in 2 quarters.
Exome Asset Management's Wave Life Sciences position peaked at $7.17M in Q4 2025.
230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.